FIELD: medicine, pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to compositions used for treatment and/or prophylaxis of chlamydium infections caused by C. pheumoniae. Pharmaceutical composition used for treatment and/or prophylaxis of chlamydium infection caused by C. pneumoniae comprises the taken phenolic compound, or extract, or fraction, or incomplete fraction comprising the taken phenolic compound or corresponding synthetic compound, or mixture of indicated compounds obtained from plants. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction obtained from plants and comprising indicated compound or corresponding synthetic compound on C. pneumoniae represents the definite percent of inhibition for formation of inclusions. The composition useful for health eliciting an anti-chlamydium effect with respect to C. pneumoniae comprises the taken phenolic compound or extract, or fraction, or incomplete fraction containing indicated compound or corresponding synthetic compound, or mixture of indicated compounds obtained from plants. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound obtained from plants on C. pneumoniae represents the definite percent for inhibition in formation of inclusions. Also, invention relates to applying the composition useful for health in preparing foodstuffs or as supplements for nutrition for every day. Also, invention relates to applying phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound or mixture of indicated compounds obtained from plants in manufacturing a medicinal agent used for treatment and/or prophylaxis of chlamydium infections caused by C. pneumoniae. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound obtained from plants on C. pneumoniae represents the definite percent in inhibition in formation of inclusions. Compositions promote to effective prophylaxis and treatment of chlamydium infections caused by C. pneumoniae.
EFFECT: valuable medicinal properties of compounds.
21 cl, 1 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING CARDIAC VALVE DISEASE | 2010 |
|
RU2491932C2 |
| CHLAMYDIAL VACCINE AND METHOD FOR ITS PREPARATION | 2016 |
|
RU2676768C2 |
| MEANS FOR CLAMIDIOSIS TREATMENT | 2016 |
|
RU2629592C1 |
| NANOANTIBODIES BINDING CHLAMYDIA TRACHOMATIS ANTIGEN, METHOD OF INHIBITING INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS | 2012 |
|
RU2487724C1 |
| RECOMBINANT PSEUDO-ADENOVIRAL PARTICLE STRAIN EXPRESSING THE CHLAMYDIA TRACHOMATIS CHIMERIC GENE MBL-CT666, A METHOD FOR PREPARING IT, AN IMMUNOGENIC COMPOSITION FOR PROTECTION AGAINST HUMAN UROGENITAL CHLAMYDIOSIS | 2019 |
|
RU2721123C1 |
| METHOD OF PREDICTING RISK OF INFECTING NASAL MUCOSA WITH CHLAMYDIA IN PATIENTS WITH CHRONIC MAXILLARY SINUSITIS | 2009 |
|
RU2425634C2 |
| DERIVATIVES OF 5-OXO-5H-[1]-BENZOPYRANO-[5,6-B]-4-OXO-4H- -[1,2]-PYRIMIDO-1,4,5,6- TETRAHYDRO-1,3-THIAZINE | 1997 |
|
RU2169732C1 |
| SYNERGISTIC COMPOSITION OF VEGETABLE ORIGIN (VARIANTS), METHOD FOR TREATMENT OF DISEASES WITH ITS USING | 2005 |
|
RU2319494C2 |
| ANTI-BURN AGENT | 2019 |
|
RU2703295C1 |
| REMEDY AGAINST CHLAMYDIA | 0 |
|
SU1795890A3 |
